These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2007-000290-32||A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally ...||2010-11-30||bad-data|
|Completed, but no date||2007-001428-11||Ensayo clínico multicéntrico, abierto, de Fase II con doxorubicina liposomal pegilada (Caelyx®) como tratamiento Primario en pacientes con cáncer de mama y antecedentes de Cardiopatía o con Edad supe...||bad-data|
|Not reported||2011-006083-45||A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer||2016-09-11||due-trials|
|Not reported||2012-000394-23||A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer||2015-10-21||due-trials|
|Ongoing||2012-001201-24||A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HE...||not-yet-due|
|Completed, but no date||2013-001036-22||PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer||bad-data|
|Ongoing||2014-000793-19||A Phase II, Randomized Study of T DM1 versus T DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer.||not-yet-due|
|Ongoing||2014-005006-38||PATRICIA: A Phase II clinical trial of palbociclib and trastuzumab with or without letrozole in postmenopausal pretreated HER2-positive locally advanced or metastatic breast cancer patients||not-yet-due|
|Ongoing||2016-003098-17||CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer.||not-yet-due|